Re-Administration of Pembrolizumab for Urothelial Carcinoma after immune-Related Myasthenia Gravis : A Case Report

Immune checkpoint inhibitors (ICIs) provide excellent benefits to the treatment of various cancer types, including urothelial carcinoma. Conversely, they can cause immune-related adverse events (irAEs), and some of them are severe or fatal. Furthermore, evidence on the safety and effectiveness of th...

Ausführliche Beschreibung

Bibliographische Detailangaben

Veröffentlicht in:	Hinyokika kiyo. Acta urologica Japonica. - 1962. - 68(2022), 9 vom: 01. Sept., Seite 295-300
1. Verfasser:	Kurokawa, Masayuki (VerfasserIn)
Weitere Verfasser:	Shimizu, Kosuke, Kitabayashi, Ryota, Ogawa, Kosuke, Okada, Yoshiyuki, Kubo, Kenichiro, Yamaguchi, Daisuke, Okubo, Kazutoshi
Format:	Online-Aufsatz
Sprache:	Japanese
Veröffentlicht:	2022
Zugriff auf das übergeordnete Werk:	Hinyokika kiyo. Acta urologica Japonica
Schlagworte:	Case Reports Journal Article Review Antibodies, Monoclonal, Humanized Antineoplastic Agents, Immunological Immune Checkpoint Inhibitors Immunoglobulins, Intravenous pembrolizumab DPT0O3T46P